Literature DB >> 31666342

Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?

Monika Engelhardt1,2, Kwee Yong3, Sara Bringhen4, Ralph Wäsch5,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31666342      PMCID： PMC6821633          DOI： 10.3324/haematol.2019.228684

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  26 in total

1.  Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.

Authors:  Joseph Mikhael; Nofisat Ismaila; Matthew C Cheung; Caitlin Costello; Madhav V Dhodapkar; Shaji Kumar; Martha Lacy; Brea Lipe; Richard F Little; Anna Nikonova; James Omel; Namrata Peswani; Anca Prica; Noopur Raje; Rahul Seth; David H Vesole; Irwin Walker; Alexander Whitley; Tanya M Wildes; Sandy W Wong; Tom Martin
Journal:  J Clin Oncol       Date:  2019-04-01       Impact factor: 44.544

Review 2.  Current developments in immunotherapy in the treatment of multiple myeloma.

Authors:  Martin Köhler; Christine Greil; Michael Hudecek; Sagar Lonial; Noopur Raje; Ralph Wäsch; Monika Engelhardt
Journal:  Cancer       Date:  2018-02-06       Impact factor: 6.860

Review 3.  Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Authors:  Alessandra Larocca; Sandra Maria Dold; Sonja Zweegman; Evangelos Terpos; Ralph Wäsch; Mattia D'Agostino; Sophia Scheubeck; Hartmut Goldschmidt; Francesca Gay; Michele Cavo; Heinz Ludwig; Christian Straka; Sara Bringhen; Holger W Auner; Jo Caers; Martin Gramatzki; Massimo Offidani; Meletios A Dimopoulos; Hermann Einsele; Mario Boccadoro; Pieter Sonneveld; Monika Engelhardt
Journal:  Leukemia       Date:  2018-04-25       Impact factor: 11.528

4.  Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma.

Authors:  Philippe Moreau; Brigitte Kolb; Michel Attal; Denis Caillot; Lotfi Benboubker; Mourad Tiab; Cyrille Touzeau; Xavier Leleu; Murielle Roussel; Carine Chaleteix; Lucie Planche; Anne Chiffoleau; June Fortin; Hervé Avet-Loiseau; Jean-Yves Mary; Cyrille Hulin; Thierry Facon
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

5.  Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.

Authors:  Joseph R Mikhael; Craig B Reeder; Edward N Libby; Luciano J Costa; P Leif Bergsagel; Francis Buadi; Angela Mayo; Sravan K Nagi Reddy; Katherine Gano; Amylou C Dueck; A Keith Stewart
Journal:  Br J Haematol       Date:  2015-02-13       Impact factor: 6.998

6.  Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Authors:  Thierry Facon; Jae Hoon Lee; Philippe Moreau; Ruben Niesvizky; Meletios Dimopoulos; Roman Hajek; Ludek Pour; Artur Jurczyszyn; Lugui Qiu; Zandra Klippel; Anita Zahlten-Kumeli; Muhtarjan Osman; Bruno Paiva; Jesus San-Miguel
Journal:  Blood       Date:  2019-02-28       Impact factor: 22.113

Review 7.  How I treat myeloma with new agents.

Authors:  Philippe Moreau
Journal:  Blood       Date:  2017-07-26       Impact factor: 22.113

8.  Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Authors:  S Bringhen; A Milan; M D'Agostino; C Ferri; R Wäsch; F Gay; A Larocca; M Offidani; S Zweegman; E Terpos; H Goldschmidt; M Cavo; H Ludwig; C Driessen; H W Auner; J Caers; M Gramatzki; M A Dimopoulos; M Boccadoro; H Einsele; P Sonneveld; M Engelhardt
Journal:  J Intern Med       Date:  2019-04-08       Impact factor: 8.989

9.  Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

Authors:  Antonio Palumbo; Francesca Gay; Federica Cavallo; Francesco Di Raimondo; Alessandra Larocca; Izhar Hardan; Arnon Nagler; Maria T Petrucci; Roman Hajek; Sara Pezzatti; Michel Delforge; Francesca Patriarca; Francesca Donato; Chiara Cerrato; Chiara Nozzoli; Zhinuan Yu; Luana Boccadifuoco; Tommaso Caravita; Giulia Benevolo; Tommasina Guglielmelli; Donatella Vincelli; Christian Jacques; Meletios A Dimopoulos; Giovannino Ciccone; Pellegrino Musto; Paolo Corradini; Michele Cavo; Mario Boccadoro
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

10.  Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.

Authors:  Sara Bringhen; Roberto Mina; Maria Teresa Petrucci; Gianluca Gaidano; Stelvio Ballanti; Pellegrino Musto; Massimo Offidani; Stefano Spada; Giulia Benevolo; Elena Ponticelli; Piero Galieni; Michele Cavo; Tommaso Caravita Di Toritto; Francesco Di Raimondo; Vittorio Montefusco; Antonio Palumbo; Mario Boccadoro; Alessandra Larocca
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.